Invivyd (IVVD) Shares Outstanding (2020 - 2026)
Invivyd's (IVVD) quarterly Shares Outstanding (Entity) came in at $294.8 million in Q2 2026, up 145.34% on a YoY basis from $120.1 million in Q2 2025, and up 71.16% quarter-over-quarter from $172.2 million in Q4 2025.
Analysis
Invivyd (IVVD) Shares Outstanding (2020 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Shares Outstanding (Entity) for 7 consecutive years, with $294.8 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Shares Outstanding (Entity) rose 145.34% year-over-year to $294.8 million; the trailing twelve-month figure through Jun 2026 stood at $294.8 million (up 145.34% YoY), and the FY2025 full-year result was $172.2 million, up 43.71% from the prior year.
- Shares Outstanding (Entity) advanced to $294.8 million in Q2 2026 per IVVD's latest filing, from $172.2 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $294.8 million in Q2 2026 and bottomed at $108.8 million in Q2 2022.
- Historically, Shares Outstanding (Entity) has averaged $131.2 million across 5 years, with a median of $119.2 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) jumped 43452.45% in 2022, then retreated 0.33% in 2023.
- Over 5 years, Shares Outstanding (Entity) stood at $109.0 million in 2022, then grew by 1.02% to $110.2 million in 2023, then advanced by 8.78% to $119.8 million in 2024, then jumped by 43.71% to $172.2 million in 2025, then soared by 71.16% to $294.8 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $294.8 million, $172.2 million, and $170.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 540.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 1.24 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 253.70 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 102.80 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 61.30 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 398.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 147.70 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | 320.44 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 320.44 Mn |
| Dec 31, 2025 | 172.21 Mn |
| Sep 30, 2025 | 170.17 Mn |
| Jun 30, 2025 | 120.02 Mn |
| Mar 31, 2025 | 119.88 Mn |
| Dec 31, 2024 | 118.56 Mn |
| Sep 30, 2024 | 119.50 Mn |
| Jun 30, 2024 | 119.36 Mn |
| Mar 31, 2024 | 115.62 Mn |
| Dec 31, 2023 | 109.53 Mn |
| Sep 30, 2023 | 109.75 Mn |
| Jun 30, 2023 | 109.45 Mn |
| Mar 31, 2023 | 108.79 Mn |
| Dec 31, 2022 | 108.27 Mn |
| Sep 30, 2022 | 108.42 Mn |
| Jun 30, 2022 | 108.17 Mn |
| Mar 31, 2022 | 107.87 Mn |
| Dec 31, 2021 | 42.62 Mn |
| Sep 30, 2021 | 61.30 Mn |
| Jun 30, 2021 | 249,769.00 |